Genova Diagnostics: The Specialty Lab the DOJ Says Paid Kickbacks to Land Naturopathic Doctor Referrals

Genova Diagnostics Inc., a North Carolina-based specialty clinical laboratory serving the functional medicine and naturopathic practitioner market, agreed to pay $36.5 million to resolve Department of Justice allegations that it paid kickbacks to practitioners in exchange for patient specimen referrals — in violation of the federal Anti-Kickback Statute and the False Claims Act.DOCUMENTED

The settlement resolved allegations arising from a whistleblower lawsuit filed under the qui tam provisions of the False Claims Act. The complaint alleged that Genova used discounted or free testing services, educational events, and other benefits of value as inducements to naturopathic doctors, functional medicine physicians, and other alternative health practitioners to send patient specimens to Genova's laboratory rather than to competing labs.

What Genova Diagnostics Does

Genova Diagnostics is not a conventional clinical laboratory. Rather than offering standard diagnostic panels covered by most insurance plans, the company has built its business around comprehensive specialty testing: multi-biomarker gastrointestinal assessments, hormone and adrenal function panels, nutritional status evaluations, and similar tests that are popular among practitioners of functional medicine and naturopathic medicine — clinical traditions that emphasize individualized, whole-body assessment and that often recommend extensive laboratory evaluation as part of treatment planning.REVIEWED

The practitioners who order these tests — naturopathic doctors, functional medicine physicians, integrative health practitioners — represent a distinct referral channel from the conventional medical system. They often operate outside standard insurance networks and order testing that patients may pay for out of pocket or through health savings accounts. The relationship between Genova and these practitioners was, according to the DOJ's complaint, structured in ways that provided financial inducements for the referral relationship rather than simply reflecting the merits of the laboratory's tests.

The Kickback Mechanism

Under the federal Anti-Kickback Statute, it is illegal for any entity receiving payment from federal healthcare programs — including Medicare and Medicaid — to offer or pay anything of value to induce referrals of business payable by those programs. The statute applies broadly to laboratories, and the range of things that can constitute prohibited inducements extends well beyond direct cash payments: discounted services, free supplies, educational sponsorships, and other benefits can all qualify as kickbacks if they are provided to practitioners in a context intended to generate referrals.DOCUMENTED

The DOJ's complaint against Genova alleged that the company provided practitioners with deeply discounted or free access to its testing panels — including tests that the practitioners could use in their own practices to evaluate potential patients — as a way of building the commercial relationship and generating referral volume. Because some patients whose specimens were directed to Genova were beneficiaries of federal healthcare programs, the laboratory's claims to Medicare or Medicaid for those specimens were tainted by the kickback arrangement, making them false claims under the False Claims Act.REVIEWED

When a laboratory's discounts to a practitioner are calibrated to the volume of specimens coming the other direction, the discount is not a pricing strategy — it is a kickback.

The Naturopathic Practitioner Market

The DOJ's case against Genova sits at the intersection of two dynamics: the growth of functional and integrative medicine as a practitioner segment, and the expanding enforcement attention regulators have given to laboratories that compete aggressively for this market. Naturopathic doctors and functional medicine physicians often order laboratory tests at higher volumes than conventional practitioners, because their clinical models emphasize comprehensive assessment. This makes them attractive as referral sources — and creates commercial incentives for laboratories to cultivate those relationships through means that may cross into kickback territory.REVIEWED

Laboratories serving this market have faced a pattern of anti-kickback enforcement over the past decade. The combination of practitioners who operate partly outside the conventional insurance system, patients who often pay out of pocket, and federal healthcare program involvement whenever any beneficiary is included in the patient population creates conditions where kickback schemes can grow substantially before detection. The False Claims Act's qui tam mechanism — which allows private individuals with inside knowledge to file lawsuits on the government's behalf and receive a portion of any recovery — has been the primary vehicle for surfacing these arrangements.

The Whistleblower's Role

The $36.5 million settlement included a share for the individual who originally filed the qui tam complaint. Whistleblowers in False Claims Act cases are entitled to between 15 and 30 percent of the government's recovery, depending on the significance of their contribution and whether the government elected to intervene in the litigation. The existence of a whistleblower complaint is typically a signal that the alleged conduct was known internally — that at least one employee or close associate of the company was aware of the arrangement and decided that filing a lawsuit was the appropriate response.DOCUMENTED

For laboratories and other healthcare service providers, the qui tam mechanism represents a significant compliance risk: any person with inside knowledge of a kickback arrangement can become a potential relator, with a direct financial incentive to report. The most effective protection is not strategic — ensuring that commercial arrangements with practitioner referral sources are structured to comply with the Anti-Kickback Statute's safe harbors, with commercial justification independent of referral volume documented in a way that can withstand regulatory scrutiny.

What Compliance Looks Like in This Space

Permissible commercial relationships between laboratories and referring practitioners do exist under safe harbors in the Anti-Kickback Statute. Volume discounts to group purchasing organizations, personal service arrangements that reflect genuine fair-market-value compensation for real services, and certain educational activities meet safe harbor requirements. But these safe harbors have specific conditions, and the common thread is that benefits provided to practitioners cannot be calibrated — directly or indirectly — to the volume or value of referrals. The DOJ's $36.5 million case against Genova Diagnostics is a reminder that specialty laboratory markets are not exempt from these requirements simply because the practitioners involved operate outside the conventional medical mainstream.

Have documents relevant to this story? Reach us through our tips channel.